Treatment Options for Painful Diabetic Neuropathy: A Review of the Latest Clinical Evidence
According to the Centers for Disease Control and Prevention (CDC), there are approximately 30.3 and 84.1 million adults in the US living with diabetes and prediabetes, respectively. About 20% of patients with diabetes will develop painful diabetic neuropathy (PDN), a debilitating, progressive chronic pain condition that significantly impacts patients’ health-related quality of life. Pharmacological treatments like anticonvulsants and antidepressants have poor efficacy, significant side effects, and high dropout rates. Minimally invasive treatment options like spinal cord stimulation (SCS) may present a possible treatment option in patients with PDN who have failed conservative treatments. This presentation will review evidence for current standard of care as well as emerging evidence for high frequency 10 kHz SCS.
- Describe the mechanism of painful diabetic neuropathy
- Cite accepted protocol for treatment
- Compare emerging studies for novel treatment
- 1.00 AAFP
- 1.00 AANP
- 1.00 ACCME (All Other)
- 1.00 ACCME (MD/DO Only)
- 1.00 ACPE Pharmacy
- 1.00 ANCC
- 1.00 APA
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.